Stability of Oseltamivir in Various Extemporaneous Liquid Preparations
Author(s): Ford Stephen M, Kloesel Lawson G, Grabenstein John D
Issue: Mar/Apr 2007 - Diabetes
View All Articles in Issue
Page(s): 164-176
Download in electronic PDF format for $65
Abstract: The purpose of this study was to determine the stability of oseltamivir, the active ingredient in Tamiflu, in contemporaneously compounded suspensions for a period of not less than 90 days. The suspension vehicles provided for the study were chosen because of ease of preparation, commercial availability, and palatability. Stability of the active ingredient was demonstrated for suspensions prepared in PCCA-Plus, PCCA Acacia, and 1% methylcellulose and was independent of storage temperature (tested temperatures were 2oC to 8oC and 25oC). A control sample of the commercial liquid form of Tamiflu was prepared, stored, and analyzed along with the samples prepared from the contents of capsules. There was no difference in the apparent stability of the two forms of the drug preparation.
Related Keywords: histamine 1 receptor inhibitor, H1 blocker, sedation, Stephen M Ford, PharmD, BCPS, BCOP, Lawson G Kloesel, RPh, BS Pharm, FIACP, John D Grabenstein, RPh, PhD, oseltamivir, antiviral agent, viral infection, virus, influenza, oral suspension vehicles, stability, storage, formulations
Related Categories: EXCIPIENTS, FORMULATIONS, PEER-REVIEWED, STABILITIES, COMPATIBILITIES, INFECTIOUS DISEASE, STORAGE